TY  - CHAP
M1  - Book, Section
TI  - Breast Cancer
A1  - Boster, Bonnie Lin
A1  - Patel, Neelam K.
A1  - Michaud, Laura Boehnke
A2  - DiPiro, Joseph T.
A2  - Yee, Gary C.
A2  - Posey, L. Michael
A2  - Haines, Stuart T.
A2  - Nolin, Thomas D.
A2  - Ellingrod, Vicki
PY  - 2020
T2  - Pharmacotherapy: A Pathophysiologic Approach, 11e
AB  - Update  SummaryThe  following  updates  to  this  chapter  were  made  on  January  25,  2021:Early  Breast  Cancer  (Stage  I  and  II),  Adjuvant  Biologic  or  Targeted  thearpy  was  updated  to  include  information  on  pertuzumab,  trastuzumab,  and  hyaluronidase-zzxLocally  Advanced  Breast  Cancer  (Stage  III)  section  was  updated  to  include  information  on  ado-trastuzumab  emtansineMetastatic  Breast  Cancer  (Stage  IV),  HER2-Targeted  Agents  section  was  updated  to  include  information  on  pertuzumab,  trastuzumab,  and  hyaluronidase-zzxf  and  margetuximab-cmkb  plus  chemotherapy,  tucatinib  plus  trastuzumab  and  capecitabine,  neratinib  plus  capecitabine,  or  fam-trastuzumab  deruxtecan-nxkiMetastatic  Breast  Cancer  (Stage  IV),  Mammalian  Target  of  Rapamycin  (mTOR)  Inhibitors  section  was  updated  to  include  information  on  alpelisibMetastatic  Breast  Cancer  (Stage  IV),  Chemotherapy  section  was  updated  to  include  information  on  sacituzumab  govitecan-hziy  and  pembrolizumab  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1191341384
ER  -